View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 10, 2019

Biogen closes $800m Nightstar Therapeutics acquisition

Biogen has closed an acquisition of Nightstar Therapeutics for around $800m, marking its entry into the ophthalmology medicines market. 

Biogen has closed an acquisition of Nightstar Therapeutics for around $800m, marking its entry into the ophthalmology medicines market.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

Nightstar Therapeutics develops adeno-associated virus (AAV) therapies for inherited retinal disorders.

The acquisition adds two mid-to-late-stage ophthalmology clinical assets, as well as preclinical programmes to Biogen’s pipeline.

Nightstar Therapeutics’ lead asset NSR-REP1 is intended to treat a rare, degenerative, X-linked inherited retinal disorder called choroideremia (CHM). The condition develops due to a loss of function in the CHM gene, which encodes the Rab escort protein-1 (REP-1).

The UK company’s second clinical asset NSR-RPGR is being developed for X-linked retinitis pigmentosa (XLRP), which is also a rare inherited retinal disorder. This disease is caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene, resulting in the loss of photoreceptors cells and retinal dysfunction.

Both CHM and XLRP primarily affect males and lack approved treatments.

Nightstar Therapeutics is also developing NSR-ABCA4, a preclinical product intended for the treatment of Stargardt disease.

Biogen CEO Michel Vounatsos said: “The acquisition of Nightstar further bolsters our pipeline and is an important step forward toward our goal of a multi-franchise portfolio across complementary modalities.

“We look forward to working now as one Biogen team with the goal of bringing breakthrough therapies to patients to slow or halt blindness across a range of inherited retinal diseases.”

The company entered an agreement to buy Nightstar Therapeutics in March this year. According to the terms of the deal, each share of the UK company was valued at $25.50.

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology